0 NASDAQ Companies - May 9, 2024Cipher Mining to Participate in the 19th Annual Needham Technology, Media, & Consumer ConferenceNEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a U.S.-based Bitcoin […]Read More
0 NASDAQ Companies - May 9, 2024Oportun Reports First Quarter 2024 Financial ResultsStrong performance versus guidance Total operating expenses declined 15% sequentially and 25% year-over-year GAAP net loss sharply reduced by $76M […]Read More
0 NASDAQ Companies - May 9, 2024Pineapple Energy Reports First Quarter 2024 Financial ResultsFirst Quarter 2024: Revenue down 40% from Q1 2023 Gross profit down 40% from Q1 2023 Operating Expenses down 31% […]Read More
0 NASDAQ Companies - May 9, 2024Rackspace Technology Reports First Quarter 2024 ResultsRevenue of $691 million in the First Quarter, down 9% Year-over-Year Private Cloud Revenue was $268 million, down 15% Year-over-Year […]Read More
0 NASDAQ Companies - May 9, 2024DoubleDown Interactive to Participate at 19th Annual Needham Technology, Media & Consumer Conference on May 16SEATTLE, May 09, 2024 (GLOBE NEWSWIRE) — DoubleDown Interactive (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher […]Read More
0 NASDAQ Companies - May 9, 2024Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateEnrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data […]Read More
0 NASDAQ Companies - May 9, 2024Karat Packaging Reports 2024 First Quarter Financial ResultsCHINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor […]Read More
0 NASDAQ Companies - May 9, 2024Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatePhase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with […]Read More
0 NASDAQ Companies - May 9, 2024Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly […]Read More
0 NASDAQ Companies - May 9, 2024MYR Group Inc. to Attend Stifel Cross Sector Insight Investor Conference in JuneTHORNTON, Colo., May 09, 2024 (GLOBE NEWSWIRE) — MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading […]Read More